AIM to AID, a nonprofit founded by Houston high school students, is launching an app to provide critical tools for refugees. Photo via Canva

A nonprofit founded by high school students in Houston is looking to provide tools to refugees at their fingertips.

AIM to AID, founded by children of immigrants to help ease the transition of immigrants and refugees to the United States, has announced the launch of its Merhaba app. The platform was created to be another tool for refugees in immersion through the convenience of a smartphone. The app is launching by March for Google Play and Apple.

Merhaba, which means “hi” in Arabic and is a general Middle Eastern greeting, aims to connect refugees to resources they need to be successful in the face of culture shock, and address any present day struggles a refugee would have when making the transition to a new life. Some of the features will include translation services, prayer compass to show Muslims the accurate direction in which to pray, and a halal finder for those to find businesses close to them that serve food that fits certain religious and dietary needs. The app also includes a tracker to find Mosques, Islamic and general clothing, bus stations, parks, banks, hospitals, and governmental offices.

The Houston-based organization was started by Lamar High School senior Ibraheem Razouki and DeBakey High School senior Zane Asadi, and is now in three continents with over 25 chapters internationally.

The first version of the app is tailored to Middle Eastern refugees, which makes the app unique in the marketplace. AIM to AID hopes as the app and the program grows, the features of the app will expand to serve the needs of diverse refugee populations.

Razouki came to the U.S. as a migrant during the Iraq war and recalls the struggle as a child to fit in because these resources weren’t available and the desperation that came with it. The application will provide mandatory needs and services to assist those of Middle Eastern and Muslim background with everyday needs.

“A lot of the needs that are being addressed in the app is a way of life for some of the refugees since they are deeply integrated into their religion, which is part of their identity,” says Razouki. ”Just having these conveniences at your disposable can enhance their way of life.”

In April, Ibraheem and other members of AIM to AID are going to Congress to pitch the application as a winner of the Congressional App Challenge.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”